Abstracts Archive - Page 807 of 2607 - ACR Meeting Abstracts

Abstract Number: 1528 • ACR Convergence 2021
Clinical Consequences of Hepatitis B Core Antibody Positivity After IVIG Administration
William West¹, Therese Posas-Mendoza², Jerald Zakem³, William Davis¹ and Robert Quinet⁴, ¹Ochsner Medical Center, New Orleans, LA, ²Ochsner Clinic Foundation, New Orleans, LA, ³Ochsner Health Systems, Metairie, LA, ⁴Ochsner Health, River Ridge, LA
Background/Purpose: Intravenous immunoglobulin (IVIG) is a blood product created by pooling of donor plasma that is used for a wide range of indications. IVIG is…
Abstract Number: 1529 • ACR Convergence 2021
Effectiveness and Safety of Pegloticase with Concomitant Immunomodulatory Therapy
Huifeng Yun¹, Brian LaMoreaux², Lang Chen³, Stephanie Ledbetter³, Megan Francis-Sedlak², Kenneth Saag³, Ted Mikuls⁴ and Jeffrey Curtis⁵, ¹University of Alabama Birmingham, Birmingham, AL, ²Horizon Therapeutics plc, Deerfield, IL, ³University of Alabama at Birmingham, Birmingham, AL, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Oral urate-lowering therapy (ULT) is one of the primary treatments for gout. Unfortunately, a proportion of patients with advanced gout are resistant to oral…
Abstract Number: 1530 • ACR Convergence 2021
Evaluation of the Possible Different Evolution of SARS-CoV-2 Infection with Tumor Necrosis Factor Inhibitors or with Rituximab in Rheumatic Patients
Simón Ángel Sánchez-Fernández¹, Luisa Marena Rojas Vargas¹, Leticia Del Olmo Pérez², Paula Virginia García Morales¹, Adela Alía Jiménez¹, José Antonio Carrasco Fernández¹ and Sandra Masegosa Casanova³, ¹Hospital La Mancha Centro, Alcázar de San Juan, Spain, ²Hospital Nuestra Señora del Prado, Talavera de la Reina, Spain, ³Hospital General de Tomelloso, Tomelloso, Spain
Background/Purpose: To assess whether two different biological therapies (BT), tumor necrosis factor inhibitor (TNFi) and ritixumab (RTX), are related to a different course and severity…
Abstract Number: 1531 • ACR Convergence 2021
New-Onset IgG Autoantibodies in Hospitalized Patients with COVID-19
Sarah Chang¹, Allan Feng¹, Wenzhao Meng², Sokratis Apostolidis², Elisabeth Mack³, Maja Artandi¹, Linda Barman¹, Kate Bennett⁴, Saborni Chakraborty¹, Iris Chang¹, Peggie Cheung¹, Sharon Chinthrajah¹, Shaurya Dhingra¹, Evan Do¹, Amanda Finck⁴, Andrew Gaano⁴, Reinhard Gessner⁵, Heather Giannini⁴, Joyce Gonzalez⁴, Sarah Greib³, Margrit Gündisch³, Alex Hsu¹, Alex Kuo¹, Monali Manohar¹, Rong Mao¹, Indira Neeli⁶, Andreas Neubauer³, Oluwatosin Oniyide², Abigail Powell¹, Rajan Puri¹, Harald Renz³, Jeffrey Schapiro⁷, Payton Weidenbacher¹, Rich Wittman¹, Neera Ahuja¹, Ho-Ryun Chung³, Pras Jagannathan¹, Judith James⁸, Peter Kim¹, Nuala Meyer², Kari Nadeau¹, Marko Radic⁶, William Robinson⁹, Upinder Singh¹, Taia Wang¹, John Wherry⁴, Chrysanthi Skevaki³, Eline Luning Prak⁴ and Paul Utz¹⁰, ¹Stanford, San Francisco, ²University of Pennsylvania, Philadelphia, PA, ³Marburg University, Marburg, Germany, ⁴UPenn, Philadelphia, PA, ⁵University of Marburg, Marburg, Germany, ⁶UTHSC, Memphis, TN, ⁷KPNC Regional Laboratory, Berkeley, ⁸Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁹Stanford University, Palo Alto, CA, ¹⁰Stanford University, Stanford, CA
Background/Purpose: Coronavirus Disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), is associated with a wide range of clinical manifestations, including autoimmune features…
Abstract Number: 1532 • ACR Convergence 2021
Methotrexate Hampers Immunogenicity to BNT162b2 mRNA COVID-19 Vaccine in Immune-Mediated Inflammatory Disease
Rebecca Haberman¹, Ramin Herati¹, David Simon², marie Samanovic¹, Michael Tuen¹, Rebecca Blank³, Sergei Koralov¹, Raja Atreya⁴, Koray Tascilar⁵, Joseph Allen¹, Rochelle Castillo⁶, Amber Cornelius¹, Paula Rackoff³, Gary Solomon⁷, Samrachana Adhikari¹, Natalie Azar⁸, Pamela Rosenthal⁹, Peter Izmirly¹⁰, Jonathan Samuels¹¹, Brian Golden¹², Soumya Reddy⁹, Markus Neurath⁴, Steven B. Abramson¹⁰, Georg Schett¹³, Mark Mulligan¹ and Jose Scher¹⁰, ¹NYU Grossman School of Medicine, New York, NY, ²Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nrnberg, Erlangen, Germany, ³New York University, New York, NY, ⁴Deutsches Zentrum fur Immuntherapie, FAU Erlangen-Nuremberg and Universitatsklinikum Erlangen, Erlangen, Germany, ⁵Friedrich Alexander University of Erlangen Nuremberg, Universitaetsklinikum Erlangen Department of Medicine-3 Rheumatology and Immunology, Erlangen, Germany, ⁶NYU Langone Health, New York, NY, ⁷NYU Langone School of Medicine, Hartsdale, NY, ⁸NYU Langone, New York, NY, ⁹NYU School of Medicine, New York, NY, ¹⁰New York University School of Medicine, New York, NY, ¹¹NYU Langone, Rye Brook, NY, ¹²NYU Langone Medical Center - NYU Hospital for Joint Diseases, New York, NY, ¹³Universitätsklinikum Erlangen, Department of Internal Medicine 3 – Rheumatology and Immunology, Erlangen, Germany, Erlangen, Germany
Background/Purpose: Patients with immune mediated inflammatory disorders (IMIDs) have an inherently heightened susceptibility to infection and may be considered high risk for developing COVID-19. While…
Abstract Number: 1533 • ACR Convergence 2021
Comparison of Hospitalization and Mortality Rate in Patients with Different Rheumatic Diseases: A Brazilian Registry Cross-Sectional Analysis
Claudia Marques¹, Ana Paula Reis², Adriana Kakehasi³, Edgard Neto⁴, Marcelo Medeiros Pinheiro⁵, Gecilmara Salviato Pileggi⁶, Gilda Ferreira⁷, Licia Maria Henrique Mota⁸, Odirlei Andre Monticielo⁹, Sandra Lúcia Ribeiro¹⁰, Felipe Omura¹¹, Adriana Marinho¹², Francinne Ribeiro¹³, Laurindo Rocha Jr¹⁴, Ana Silvia Martins¹⁵, Michel Yazbek¹⁶, Mariana Souza¹⁷, Nathália Sacilotto¹⁸, Samuel Shinjo¹⁹, Lilian Valadares²⁰, Ana Silva²¹, Danielle Christine de Brito²², Viviane de Souza²³, Carolina Costa²⁴, Samia Studart²⁵, Antônio Ximenes²⁶ and Ricardo Xavier²⁷, ¹Hospital das Clnicas - Universidade Federal de Pernambuco - UFPE, Recife, Brazil, ²Centro Universitrio de Braslia- UniCEUB, Brasilia, Brazil, ³Federal University of Minas Gerais, Belo Horizonte, Brazil, ⁴UNIFESP, São Paulo, Brazil, ⁵Universidade Federal de São Paulo, São Paulo, Brazil, ⁶FACISB, Ribeirao Preto, Brazil, ⁷Federal University of Minas Gerais, Belo Horizonte, Brazil, ⁸Universidade de Brasília, Brasilia, Brazil, ⁹Serviço de Reumatologia do Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ¹⁰Universidade Federal do Amazonas, Amazonas, Brazil, ¹¹Clinica Omura, São Paulo, Brazil, ¹²FUNDHACRE, Rio Branco, Brazil, ¹³UERJ, Rio de Janeiro, Brazil, ¹⁴Instituto de Medicina Integral Professor Fernando Figueira - IMIP, Recife, Brazil, ¹⁵UFU, Uberlandia, MG, Brazil, ¹⁶UNICAMP, Campinas, Brazil, ¹⁷SCBH, Belo Horizonte, Brazil, ¹⁸Instituto de Assistência Médica ao Servidor Público Estadual, São Paulo, Brazil, ¹⁹Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²⁰HOSPITAL GETULIO VARGAS, Recife, Brazil, ²¹UFG, GOIANIA, Goias, Brazil, ²²UFPB, Joao Pessoa, Brazil, ²³UFJF, JUIZ DE FORA, Brazil, ²⁴UFES, Vitoria, Brazil, ²⁵HOSPITAL GERAL DE FORTALEZA, Fortaleza, Brazil, ²⁶CLINICA CIP, Goiania, Brazil, ²⁷Departamento de Reumatologia, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
Background/Purpose: The COVID-19 pandemic has brought uncertainties to the rheumatological practice, and despite the large number of publications to date, many questions remain unanswered. One…
Abstract Number: 1534 • ACR Convergence 2021
Severity Factors of Covid-19 Infection in Rheumatic Immune-mediated Inflammatory Diseases: Study in a Single University Hospital
David Martinez-Lopez¹, Diana Prieto-Peña¹, Lara Sánchez-Bilbao¹, Carmen Álvarez-Reguera¹, Alba Herrero-Morant¹, Fabricio Benavides-Villanueva¹, Cristina Corrales-Selaya¹, Martin Trigueros-Vazquez¹, Miguel Ángel gonzalez-Gay², Ricardo Blanco³ and Reinhard Wallmann⁴, ¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ³Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁴Cantabria Health Service, Santander, Spain
Background/Purpose: Severity factors for COVID-19 have been widely studied in the general population. However, the severity factors and characteristics of COVID-19 in patients with rheumatic…
Abstract Number: 1535 • ACR Convergence 2021
Low Incidence and Transient Elevation of Autoantibodies Post mRNA COVID-19 Vaccination
Rebecca Blank¹, Rebecca Haberman², Rochelle Castillo², marie Samanovic³, Parvathy Vasudevanpillai Girija⁴, Paula Rackoff¹, Gary Solomon⁵, Natalie Azar⁶, Pamela Rosenthal⁷, Peter Izmirly⁴, Jonathan Samuels⁸, Brian Golden⁹, Soumya Reddy⁷, Steven B. Abramson⁴, Mark Mulligan³ and Jose Scher⁴, ¹New York University, New York, NY, ²NYU Langone Health, New York, NY, ³NYU Grossman School of Medicine, New York, NY, ⁴New York University School of Medicine, New York, NY, ⁵NYU Langone School of Medicine, Hartsdale, NY, ⁶NYU Langone, New York, NY, ⁷NYU School of Medicine, New York, NY, ⁸NYU Langone, Rye Brook, NY, ⁹NYU Langone Medical Center - NYU Hospital for Joint Diseases, New York, NY
Background/Purpose: Recent studies have shown high rates of autoantibody production in patients hospitalized with COVID-19, including antinuclear antibodies (ANA) and antibodies associated with antiphospholipid syndrome.…
Abstract Number: 1536 • ACR Convergence 2021
Acceptability of Vaccines Against COVID-19 and Other Preventable Infections Among Patients with Rheumatic Disease
Sara Tedeschi¹, Jack Ellrodt¹, Jacklyn Stratton¹, Leah Santacroce¹, Paulette Chandler¹, Ellen Gravallese² and Daniel Solomon³, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Harvard Medical School, Chestnut Hill, MA, ³Brigham and Women's Hospital, Newton, MA
Background/Purpose: Vaccination against preventable infections is widely recommended for patients with systemic rheumatic disease. The COVID-19 pandemic has highlighted variability in attitudes toward vaccination, particularly…
Abstract Number: 1537 • ACR Convergence 2021
Impact of COVID-19 Infection on Patient-Reported Outcomes in Rheumatic Disease Patients: A Cross Sectional Study
Elaine Husni¹, Cassandra Calabrese², Brittany Lapin¹, Elizabeth Kirchner³ and Leonard Calabrese¹, ¹Cleveland Clinic, Cleveland, OH, ²Cleveland Clinic Foundation, Cleveland Heights, OH, ³CCF, Cleveland, OH
Background/Purpose: The persistence of symptoms following COVID 19 is an area of great interest yet remains poorly understood. Long COVID symptoms are dominated by fatigue…
Abstract Number: 1538 • ACR Convergence 2021
Adverse Events After SARS-CoV-2 Vaccination Among Rheumatology Outpatients in New York City
Medha Barbhaiya¹, Deanna Jannat-Khah¹, Jonah Levine¹, Huong Do¹, Lindsay Lally¹, Vivian Bykerk² and Lisa Mandl¹, ¹Hospital for Special Surgery, New York, NY, ²Division of Rheumatology, Hospital for Special Surgery, New York City, NY
Background/Purpose: Vaccination against SARS-CoV-2 is important for patients with systemic rheumatic diseases (SRDs), who may be at increased risk of severe outcomes post-COVID-19 infection. However,…
Abstract Number: 1539 • ACR Convergence 2021
High Disease Activity, as Assessed by RAPID3, Increases Risk of Hospitalization and Predicts Lower Chance of Recovery from COVID-19 in a Cohort of Tertiary Care Rheumatology Patients
Matas Orentas¹, Sonali Khandelwal², Michael Grant², Yanyu Zhang¹, Najia Shakoor² and Sobia Hassan¹, ¹RUMC, Chicago, IL, ²Rush University, Chicago, IL
Background/Purpose: There is a need to understand which patients with rheumatologic diseases may be at highest risk for poor COVID-19 related outcomes so that both…
Abstract Number: 1540 • ACR Convergence 2021
Antibody Response After SARS-CoV-2 Infection in Patients with Rheumatic Diseases: A Multicenter, Nationwide Study
Ana Rita Cruz-Machado¹, Sofia Carvalho Barreira¹, Marc Veldhoen², Matilde Bandeira¹, Catarina Duarte³, Maria Rato⁴, Bruno Fernandes⁵, Salomé Garcia⁴, Filipe Pinheiro⁴, Miguel Bernardes⁴, Nathalie Madeira⁶, Cláudia Miguel⁶, Rita Torres⁷, Ana Bento Silva⁷, Carolina Mazeda⁸, Filipe Cunha Santos⁹, Marlene Sousa¹⁰, Hugo Parente¹¹, Maria José Santos¹², João Eurico Fonseca¹³ and Vasco C Romão¹³, ¹Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon Academic Medical Center; Rheumatology Research Unit, Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal, ²Instituto de Medicina Molecular, João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal, ³Rheumatology Research Unit, Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal, ⁴Rheumatology Department, Centro Hospitalar Universitário de São João EPE, Porto, Portugal, ⁵Rheumatology Department, Centro Hospitalar Universitário de São João EPE, Braga, Portugal, ⁶Rheumatology Department, Instituto Português de Reumatologia, Lisbon, Portugal, ⁷Rheumatology Department, Hospital de Egas Moniz, Centro Hospitalar Lisboa Ocidental, Lisbon, Portugal, ⁸Rheumatology Department - Centro Hospitalar do Baixo Vouga and Ibimed, Institute for Biomedicine, University of Aveiro, Aveiro, Portugal, ⁹Rheumatology Department, Local Health Unit of Guarda, Guarda, Portugal, ¹⁰Rheumatology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal, ¹¹Rheumatology Department, Unidade Local de Saúde do Alto Minho, Ponte de Lima, Portugal., Ponte de Lima, Portugal, ¹²Rheumatology Department, Hospital Garcia de Orta, Almada, Portugal, ¹³Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon Academic Medical Centre and European Reference Network on Rare Connective Tissue and Musculoskeletal Diseases Network (ERN-ReCONNET); Rheumatology Research Unit, Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal
Background/Purpose: The development and duration of humoral immunity after SARS-CoV-2 natural infection remains of interest. For the general population, available data suggest a robust immune…
Abstract Number: 1541 • ACR Convergence 2021
Preliminary Criteria for Macrophage Activation Syndrome Associated with Coronavirus Disease-19
Shirkhan Amikishiyev¹, Mehmet Guven Gunver², Murat Bektas¹, Sarvan Aghamuradov¹, Burak Ince¹, Nevzat Koca¹, Ege Sinan Torun¹, Numune Aliyeva¹, Selma Sari¹, Cigdem Cetin³, Banu Cicek Yalcin Dulundu¹, Rabia Deniz⁴, Fatih Kemik⁴, Besim Fazil Agargun⁴, Ubeyde Ayse Gulseren⁴, Beliz Besisik⁴, Onur Alkan⁴, Ceren Bağrıaçık⁴, Yavuz Burak Tor⁴, Naci Senkal⁴, Yunus Catma⁴, Gorkem Durak⁵, Sevim Mese⁶, Ali Agacfidan⁶, Murat Kose⁴, Mustafa Erelel⁷, Arif Atahan Çağatay⁸, Sevgi Kalayoglu Besısık⁹, Figen Esen⁷ and Ahmet Gül¹⁰, ¹Istanbul Faculty of Medicine, Istanbul University, Division of Rheumatology, İstanbul, Turkey, ²Department of Biostatistics, Istanbul Medical Faculty, İstanbul, Turkey,, Istanbul, Turkey, ³Division of Rheumatology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey, ⁴Istanbul Faculty of Medicine, Istanbul University, Department of Internal Medicine, İstanbul, Turkey, ⁵Istanbul Faculty of Medicine, Istanbul University, Department of Radiology, İstanbul, Turkey, ⁶Istanbul Faculty of Medicine, Istanbul University, Department of Medical Microbiology, Division of Virology and Fundamental Immunology, İstanbul, Turkey, ⁷Istanbul Faculty of Medicine, Istanbul University, Department of Anesthesiology, İstanbul, Turkey, ⁸Istanbul Faculty of Medicine, Istanbul University, Department of Infectious Diseases and Clinical Microbiology, İstanbul, Turkey, ⁹Istanbul Faculty of Medicine, Istanbul University, Division of Hematology and Therapeutic Apheresis Unit, İstanbul, Turkey, ¹⁰Division of Rheumatology, Istanbul University Istanbul School of Medicine, Istanbul, Turkey
Background/Purpose: COVID-19 runs a severe disease associated with acute respiratory distress syndrome in a subset of patients, and a hyperinflammatory response developing in the second…
Abstract Number: 1542 • ACR Convergence 2021
Does Adjustment to Dosing and Timing of Immunomodulatory Drugs Impact Immunogenicity of COVID19 Vaccines in Patients with Autoimmune and Inflammatory Rheumatic Disease (AIIRD)?
Andrew Laster¹, Gordon Lam¹, Sarah McCarter¹, Heather Gladue², Ahmad Kashif¹, Erin Siceloff¹, Victoria Lackey², Cheryl Robertson², Ashley Toci¹ and Leonard Calabrese³, ¹Arthritis and Osteoporosis Consultants of the Carolinas, Charlotte, NC, ²Arthritis & Osteoporosis Consultants of the Carolinas, Charlotte, NC, ³Cleveland Clinic, Cleveland, OH
Background/Purpose: Clinical trials leading to approval of the COVID19 vaccines did not include immunocompromised individuals. Concerns have been raised that immunogenicity of the vaccines may…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].